Christopher Ho, MD
Dermatology · Los Angeles, CANPI 1679507537
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $646,746 of the $730,511 with a category attached, or 88.5%. 28 manufacturers reported payments, led by Amgen at 42.1% of the total. Reporting peaked in 2019 at $205,909 and has fallen 89.3% since, to $22,056 in 2025. Among dermatology clinicians in CA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 1,324 payments — averaging $551.75 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$307K
- AbbVie$169K
- Bristol Myers Squibb$98K
- Pfizer$58K
- Lilly USA, LLC$44K
- Arcutis Biotherapeutics, Inc.$21K
- plus $33K from 22 others
Across 65 payments — averaging $20,124 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- E.r. Squibb & Sons, L.L.C.$875K
- Taro Pharmaceuticals USA, Inc.$185K
- Bausch Health US, LLC$104K
- Sun Pharmaceutical Industries Inc.$88K
- Dr.reddy's Laboratories,inc.$43K
- LEO Pharma AS$8K
- plus $5K from 2 others
What the payments were for
- Consulting fees$30,6594%
- Speaking & faculty fees$646,74689%
- Travel & lodging$24,8503%
- Food & beverage$27,9224%
- Education$3350%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen | 408 | $307,441 |
| AbbVie(2 entities) | 374 | $168,782 |
| Bristol Myers Squibb | 116 | $98,136 |
| Pfizer | 114 | $58,035 |
| Lilly USA, LLC | 78 | $43,874 |
| Arcutis Biotherapeutics, Inc. | 26 | $20,764 |
| Novartis | 53 | $16,413 |
| E.r. Squibb & Sons, L.L.C. | 11 | $8,555 |
| Dermavant Sciences, Inc. | 3 | $2,700 |
| UCB, Inc. | 19 | $2,638 |
| Sanofi | 20 | $583 |
| Regeneron Healthcare Solutions, Inc. | 17 | $457 |
| Sun Pharmaceutical Industries Inc. | 23 | $455 |
| Janssen Scientific Affairs, LLC | 3 | $373 |
| Johnson & Johnson | 22 | $323 |
| Incyte Corporation | 8 | $241 |
| EPI Health, LLC | 5 | $213 |
| Journey Medical Corporation | 2 | $116 |
| Galderma Laboratories, L.p. | 5 | $95 |
| LEO Pharma Inc. | 5 | $83 |
| Dermira, Inc. | 3 | $56 |
| Mayne Pharma Commercial LLC | 2 | $41 |
| Ortho Dermatologics, A Division Of Bausch Health US, LLC | 2 | $35 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $27 |
| Boehringer Ingelheim | 1 | $26 |
| Merck | 1 | $18 |
| Almirall LLC | 1 | $17 |
| Merz North America, Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$730,511 in reported general payments places this provider in the 95th percentile of 1,875 dermatology providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other dermatology in Los Angeles
- April ArmstrongLos Angeles$2.3M
- Jennifer HsiaoLos Angeles$746K
- Howard SofenLos Angeles$345K
- Nada ElbulukLos Angeles$297K
- Derek JonesLos Angeles$272K
- Pearl GrimesLos Angeles$256K
- Paul YamauchiSanta Monica$2.9M
- Jennifer SoungSanta Ana$2.8M
- Robert GreenbergLivermore$2.6M
- Neal BhatiaSan Diego$2.5M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.